Back
Conference posters
2011 posters
Bate, J.; Ryall, A.; Metcalf, D.; Lazari, V.; McAllister, G.; Lamers, M.; Jarvis, R.; Wityak, J.; Kiselyov, A.; Dominguez, C.; Munoz-Sanjuan, I. A screening cascade to identify true activators of SIRT1.
Richardson, C M.; Lipkin, M J.; Hughes, M J.; Sheppard, D W. Shape-based profiling of fragment libraries.
McDonald, N.; Nichols, C.; Leiper, J.; Hardick, D.; Whittaker, B.; Blurton, P.; Steele, C.; Caddick, S. DDAH1 as a target for Sepsis.
Mitchell, D R.; Harris, C J.; Kosugi, T.; Imai, M.; Makino, H.; Kambe, M.; Fujino, A.; Suzuki, N.; Kataoka, K. MAPKAP-K2 as an anti-inflammatory target: discovery of selective pyrazolo[i,5-a]pyrimidine inhibitors derived from a focused library.
MacLeod, A M.; Mitchell, D R.; Palmer, N J.; Van de Poël, H.; Leyssen, P.; De Palma, A.; Neyts, J. Identification of a novel series of compounds with potent antiviral activity for the treatment of picornavirus infections.
Ahrens, T.; Beyer, K.; Bergner, A.; Sheppard, D.; Dunsmore, C.; Cotton, G.; Fasler, S.; Hafenbradl, D. Fluorescence lifetime assays - added value for drug discovery programs addressing epienetic targets.
Beyer, K S.; Ahrens, T.; Bergner, A.; Fasler, S.; Hafenbradl, D. HMTs and histone demethylases - analysis of epigenetic targets on the LabChip®3000 platform and in orthogonal assay formats.
Nickel, B.; Falk, C.; Jösch, C. A transcription factor platform for compound profiling.
D, Todd.; R, Jarvid.; C, Richardson.; Gowers, I.; Turney, J.; Lamers, M.; McAllister, G.; Flynn, G.; Fischer, D.; Sheppard, D.; Bürli, R.; Kiselyov, A.; Bard, J. TrkB screening assays for the identification and characterization of small molecule BDNF mimetics and/or modulators.
Cronk, D.; Aziz, O.; Vann, J.; Pett, H.; Wong, M.; Gowers, I.; Martin, R.; McAllister, G.; Thomas, E.; Stott, A.; Haughan, A.; Stones, L.; Vater, H.; Wall, M.; Allen, D.; Breccia, P.; Raphy, G.; Richardson, C.; Matthews, K.; Yates. D.; Kiselyov, A.; Bard, J.; Beconi, M.; Beaumont, V.; Dominguez, C.; Munoz-Sanjuan, I.; Bürli, R. Selective HDAC4 inhibitors as potential therapeutics for Huntington’s disease.
Ahrens, T.; Beyer, KS.; Bergner, A.; Fasler, S.; Hafenbradl, D. Efficient hit finding approaches for HMTs.
Bergner, A.; Sheppard, D.; Slater, M. EpiRoadmap: Integration of chemogenomics-based approaches for epigentic targets.
Hafenbradl, D.; Ahrens, T.; Beyer, KS.; Brodbeck, D.; Fasler, S. Fluorescence lifetime assays – an attractive addition to the toolbox of fragment screening technologies.
Pollack, S.; Lamers, M.; Ritchie, A.; Mueller, I.; Lock, C.; Sheppard, D.; Beyer, K.; Blurton, P.; Hubbard, P.; Cronk, D.; Bürli, R.; Todd, D. p38a: A fragment-based drug discovery case study at BioFocus.
2010 posters
Pollack, S.; Lamers, M.; Ritchie, A.; Mueller, I.; Lock, C.; Shepaprd, D.; Blurton, P.; Beyer, K.; Cronk, D.; Burli, R.; Todd, D. p38alpha: a fragment-based drug discovery case study at BioFocus.
Baader, M.; Jerabek-Willemsen, M.; Duhr, S.; Mueller, I.; Lamers, M.; Pollack, S.; Burli, R. Evaluation of a new optical microscale thermophoresis technology for fragment-based drug discovery.
Kemmler, M.; Eckard, P.; Lentzen, H.; Hafenbradl, D. Pathway specific natural products in oncology.
Garo, E.; Schuhmann, I.; Bergner, A.; Hafenbradl, D. High-throughput natural product: use of ACD/Labs database and LIMS in the dereplication workflow.
Nickel, B.; Falk, C.; Jösch, C. A transcription factor platform for compound profiling.
Ahrens, T.; Brodbeck, D.; Beyer, K.; Lamers, M.; Sheppard, D.; Fasler, S.; Hafenbradl, D. Fluorescence lifetime assays - and attractive addition to the panel of drug discovery technologies. Case studies with a metalloprotease and a kinase.
Gardener, M.; Clark, G.; Southan,A.; Dijkstra, S.; de Groot, A.; Callamaras, N.; Nistor, G.; Poole, A.; Siegenthaler, M.; Frederickson, C.; Keirstead, H.; Fischer, D. F. Electrophysiological and immunocytochemical characterization of human stem cell-derived motor neurons.
Doyle, K.; Jones, G.; Russell, M.; Peach, J.; Van de Poël, A.; Molyneaux, C.; Macritchie, J.; MacLeod, A.; Shearer, J.; Cronk, D.; Clark, G.; Beresford, A.; de Hostos, E.; Nguyen, T.; Brown, D. Inhibitors Of The CFTR Chloride Ion Channel As Potential Treatment For Acute Secretory Diarrhea: Development Of 6-membered Heterocycles.
Doyle, K.; Jones, G.; Russell, M.; Peach, J.; Van de Poël, A.; Molyneaux, C.; Macritchie, J.; MacLeod, A.; Shearer, J.; Cronk, D.; Clark, G.; Beresford, A.; de Hostos, E.; Nguyen, T.; Brown, D. Inhibitors Of The CFTR Chloride Ion Channel As Potential Treatment For Acute Secretory Diarrhea: Development Of 5-membered Heterocycles Suitable For Pre-clinical.
Pril, de, R.; Lekkerkerker, A.; Frische, E.; Steenhoven, van, D.; Maghrani, I.; Perera, T.; Arts, J.; Page, M.; Fischer, D.; Janssen, R. Evaluation.Screen for inhibitors of cell migration in cancer metastasis using adenoviral knock-down.
Cronk, D.; Pollack, S.; Lamers, M.; Ritchie, A.; Mueller, I.; Shepaprd, D.; Hardick, D.; Blurton, P.; Martin, R.; Todd, D. p38alpha: a fragment-based drug discovery case study at BioFocus.
Eckard, P.; Lentzen, H.; Hafenbradl, D. Natural products targeting oncology pathways.
Brodbeck, D.; Nufer, O.; Ryall, A.; Shearer, J.; Fasler, S.; Cronk, D. Label free technology: value added information in the drug discovery process.
Ryall, A.; Shearer, J.; Brodbeck, D.; Nufer, O.; Cronk, D.; Fasler, S. Label free technology: the weird and wonderful world of cell signaling.
Ryall, A.; Daly, K.; Shearer, J.; Cronk, D. False positives from a homogenous time resolved fluorescence screen due to a compound and serum interaction.
Hafenbradl, D.; Ahrens, T.; Fasler, S.; Parel, S.; Bergner, A.; Pollack, S. Epigenetics targets – efficient hit-finding approaches.
Eckard, P.; Beyer, K.; Bergner, A. Are natural products delivering? Experiences and recommendations from 27 screening campaigns.
2009 posters
Fasler, S.; Witzig, R.; Beyer, K.; Tessari, M.; Sammut, S.; Fischer, D.; Eckard, P. A unique natural product platform applied to the discovery of correctors of mutant cystic fibrosis transmembrane conductance regulator.
Kemmler, M.; Duffy, S.; Avery, V M.; Witzig, R.; Beyer, K.; Bathurst, I.; Eckard, P. A unique natural product platform applied to the discovery of novel compounds with activity against the malaria parasite, plasmodium falciparum.
Griffioen, S.; Mille-Baker, B.; Vella, G.; Fischer, D F.; Janssen, R A J. Identification Of Compounds Enhancing Utrophin Expression In Primary Human Skeletal Muscle Cells.
Brady, J.; Allen, C.; Shivakumar, R.; Viley, A.; Peshwa, M.; Clark, G.; Dowler, S.; Clark, C.; Clarke, S.; Crowley, L.; Lawrence, A.; Maidment, S.; Southan, A. Rapid Automated Development of Cell Based Assays for Screening GPCRs, Ion Channels and Other Target Molecules Using the MaxCyte® STX™ Scalable Transient Transfection System
Southan, A.; Maidment, S.; Dowler, S.; Gardener, M.; Lawrence, A.; Aziz, O.; von Will, T.; Clark, G. Using Inducible Expression Vector Technology To Create Stable Cell Lines ExpressingKCNQ2/3, KCNQ4, And KCNQ3/5 Currents Suitable For Automated ElectrophysiologyPlatforms.
Dijkstra, S.; de Groot, A.; Gardener, M.; Clark, G.; Southan, A.; Callamaras, N.; Nistor, G.; Poole, A,; Siegenthaler, M.; Frederickson, C.; Keirstead, H.; Fischer, D F. Development of a High-throughput Assay for ALS Target Discovery using Human Stem cell-derivedMotor Neurons.
Print to HTML
Print as PDF
Send to a friend